The final session on the first day of Spring Dermatology Week 2024, saw Shawn Kwatra, MD; Joseph Merola, MD, MMSc, FAAD, FACR; Mital Patel-Cohen, MD; and Vishal Patel, MD, discuss their latest case reports in, “Complex Dermatology Cases.”
The final session on the first day of Spring Dermatology Week 2024, saw Shawn Kwatra, MD; Joseph Merola, MD, MMSc, FAAD, FACR; Mital Patel-Cohen, MD; and Vishal Patel, MD, discuss their latest case reports in, “Complex Dermatology Cases.”
A recent systematic review and meta-analysis offers insights into the relationship between vitiligo and nonmelanoma skin cancer, which can be used to enhance patient education.
A recent systematic review and meta-analysis offers insights into the relationship between vitiligo and nonmelanoma skin cancer, which can be used to enhance patient education.
The US Food and Drug Administration has approved Eli Lilly’s EBGLYSS (lebrikizumab-lbkz), an IL-13 inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and children.
The US Food and Drug Administration has approved Eli Lilly’s EBGLYSS (lebrikizumab-lbkz), an IL-13 inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and children.
In our next segment of the ElderDerm Podcast, listen to co-hosts Dr Adam Friedman and Jaya Manjunath discuss what shared decision-making is, and why it is important in dermatology.
In our next segment of the ElderDerm Podcast, listen to co-hosts Dr Adam Friedman and Jaya Manjunath discuss what shared decision-making is, and why it is important in dermatology.
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.
Assess your understanding of early skin barrier interventions in infants and the clinical rationale for prompt treatment of atopic dermatitis in young children, including implications for long-term disease outcomes.
Assess your understanding of early skin barrier interventions in infants and the clinical rationale for prompt treatment of atopic dermatitis in young children, including implications for long-term disease outcomes.